Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NMPA Approval

Recombinant Mycobacterium Tuberculosis Fusion Protein(EC)

Approval Number

国药准字S20200006

Company安徽智飞龙科马生物制药有限公司

Registration Date

April 23, 2020

Drug Information

Generic Name

重组结核杆菌融合蛋白(EC)

Trade Name

宜卡

Dosage Form

注射剂

Strength

每瓶1.0ml。每1次人用剂量为0.1ml,含5U重组结核杆菌融合蛋白(EC)。

Drug Type

生物制品

Registration Date

April 23, 2020

Company Information

Applicant Company

Company Name安徽智飞龙科马生物制药有限公司

Company Address

安徽省合肥市高新区明珠大道5008号

Manufacturing Company

Company Name安徽智飞龙科马生物制药有限公司

Company Address

合肥市高新区浮山路100号

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy

重组结核杆菌融合蛋白(EC) - NMPA 批准文号 | MedPath